Age at vaccination (years); median (min, p25, p75, max) | 60 (26, 54, 69, 76) |
Sex (# males/# females) | 19/21 |
Delay between vaccination and transplantation (months); median (min, p25, p75, max) | 31 (6, 14, 42, 57) |
Donor type (# MSD/MUD/ MMUD/Haplo) | 8/26/1/5 |
Donor age at transplantation (years); median (min, p25, p75, max) | 34 (18, 23, 46, 62) |
Conditioning regimen (# patients) | |
Fludarabine + 2 Gy TBI | 5 |
Fludarabine + Melphalan | 18 |
Fludarabine + busulfan | 4 |
Cyclophosphamide + 12 Gy TBI | 6 |
Thiotepa + busulfan + fludarabine | 2 |
Sequential | 3 |
Fludarabine + Cyclophosphamide + 2 or 4 Gy TBI | 2 |
ATG (# yes/no) | 29/11 |
PTCY (# yes/no) | 6 /34 |
Chronic GVHD | |
Never/only mild | 29 |
Prior moderate/severe solved* | 2 |
Ongoing moderate/severe | 9 |
Rituximab (none or ≥ 2yrs, ≥ 1 but < 2 yrs, > 6 months but < 1 yr), # of patients | 28, 5, 7 |
Systemic immunosuppression at inclusion | |
None | 26 |
Tacrolimus | 5 |
Photopheresis | 1 |
Photopheresis + mPDN < 32 mg/day | 1 |
MMF | 1 |
MMF + mPDN < 32 mg/day | 1 |
Sirolimus | 1 |
Sirolimus + mPDN < 32 mg/day | 2 |
Photopheresis + ruxolitinib | 2 |